Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIBIL: FOLFIRI vs 5-FU + folinic acid as second-line therapy in biliary tract cancer
2015-004028-69Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Oct 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, fluorouracil and folinic acid in biliary cancer (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Progression-free survival (PFS) in FOLFIRI arm. Started Oct 2016; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acid
03
Conditions
biliary cancer
Beyond the preview
Go deeper on 2015-004028-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004028-69.